| Controls (n = 186) | CHD group (n = 264) |
---|
Before treatment | After treatment |
---|
TG (mmol/l) | 1.15 ± 0.35 | 1.58 ± 0.58* | 1.14 ± 0.71§
|
TC (mmol/l) | 4.11 ± 0.37 | 5.14 ± 0.49* | 4.35 ± 0.53§
|
HDL-C (mmol/L) | 1.37 ± 0.31 | 1.10 ± 0.25* | 1.29 ± 0.27§
|
LDL-C (mmol/L) | 2.00 ± 0.51 | 3.1 ± 0.27* | 2.32 ± 0.30§
|
VLDL-C (mmol/L) | 0.75 ± 0.21 | 1.03 ± 0.24* | 0.78 ± 0.16§
|
MMP-9 (ng/ml) | 40.78 ± 9.72 | 78.17 ± 21.43* | 60.32 ± 20.30§
|
TNF-α (pg/ml) | 81.23 ± 39.07 | 136.95 ± 52.41* | 102.37 ± 47.19§
|
IL-10 (pg/ml) | 32.18 ± 12.15 | 98.65 ± 34.79* | 50.31 ± 24.28§
|
- Values are expressed as mean ± SD. Comparison between controls and CHD subjects were by unpaired student T-test; comparison between before and after treatment of statin were by paired student T-test. *P <0.0001 compared with control group; §
P <0.0001 compared with before treatment. CHD coronary heart disease, MMP9 matrix metalloproteinase 9, IL-10 interleukin-10, TNF-α TNF-alpha, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol